Navigation Links
MedImmune Expands Scientific and Engineering Leadership
Date:12/20/2007

tion on a global level. Before joining Amgen, Mr. Skibo served in engineering management positions focused on pharmaceuticals and bioscience at Skanska, Inc; Foster Wheeler Corp.; Life Sciences International, Inc.; A.D. Skibo & Associates, Inc.; and Genentech, Inc. Mr. Skibo holds a master of science degree in chemical engineering with a specialty in biomedical engineering and a bachelor of science degree in organic chemistry, both from Massachusetts Institute of Technology.

Management Promotion

As vice president, infectious disease research, Dr. Suzich is responsible for overseeing MedImmune's research in the development of antibodies and antibody-like molecules for the prophylaxis and treatment of infectious disease. Since joining MedImmune in 1988 in the role of scientist, she has held several positions of increasing responsibility, most recently as senior director, infectious disease research. During her tenure with the company she has been involved in many key development programs, including Synagis(R) (palivizumab) and the virus-like particle technology that is the basis of the new human papillomavirus (HPV) vaccines used to prevent cervical cancer. Dr. Suzich holds a doctorate in biochemistry from Purdue University and graduated magna cum laude with a bachelor of science degree in biology from Susquehanna University.

New Cambridge Site Leadership Team

MedImmune also announced today that following the integration of CAT into MedImmune, several personnel were appointed to the new Cambridge site leadership team under the guidance of John Stageman, Ph.D., vice president and interim site head.

Dr. Stageman has nearly 30 years of experience in R&D management throughout AZ and its predecessor companies, having pioneered large-scale biotechnology process development and scale-up at the start of his career. He entered the pharmaceutical business in 1993 rising through a number of senior roles in both drug discovery and development pr
'/>"/>

SOURCE MedImmune
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
4. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
5. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
8. Rohm and Haas Expands in India
9. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
10. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
11. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2015)... Broccoli sprout extract protects against oral cancer in ... healthy human volunteers, the University of Pittsburgh Cancer ... announced today at the American Association for Cancer ... The promising results will be further explored in a ... risk for head and neck cancer recurrence later this ...
(Date:4/19/2015)... 2015 New court documents issued by ... that Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) continue to mount ... District of South Carolina. According to the April 15th ... in the proceeding on behalf of individuals who allegedly ... the cholesterol-lowering statin. This represents an increase of 110 ...
(Date:4/19/2015)... (PRWEB) April 19, 2015 Family and friends ... for Brains in Memory of Brad Baddeley event to ... Aneurysm Foundation. , Bowling for Brains is cheduled to take ... 4700 Dudley Street in Lincoln, Nebraska. Participants may arrive at ... to 3:00pm. , The cost is only $4 per game ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Carinsurancequotesinfo.com has ... insurance can cover physical injuries caused by a ... excellent financial coverage for a vehicle. A policy can ... by an accident. Drivers should always carry appropriate coverage ... insurance policy can be bought with several important riders ...
(Date:4/18/2015)... Review of Ophthalmology magazine and Abbot ... Success’ program for cataract surgeons attending the American Society ... where eye surgeon Jeffrey L. Martin, MD will serve ... Martin is the Managing Partner of North Shore Eye ... Martin to lead this year’s discussion on the latest ...
Breaking Medicine News(10 mins):Health News:Preventing Cancer with Broccoli Sprout Extract 2Health News:Preventing Cancer with Broccoli Sprout Extract 3Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 2Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 3Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2
... ULURU Inc. (Amex:,ULU) announced today that its ... Back Offer, whereby the Company will offer to ... shares of common stock. This,program reflects ULURU,s desire ... communications costs and the potential costs,which often deter ...
... may actually be in the candy dish. In ... Heart Association conference in Orlando shows that people at ... kept the wrappers in plain sight The sneakiest, creepiest surprise ... In a study being presented this Saturday ...
... almost half of patients, study found , TUESDAY, Oct. 30 ... for treating people with what,s known as cytokine-refractory metastatic kidney ... poor response to drug treatment. , Axitinib is a selective ... receptors 1, 2 and 3. , As reported in ...
... Pa., Oct. 30 ViroPharma Incorporated,(Nasdaq: VPHM ) reported today ... 2007. Key events since June 30, 2007 include:, Clinical:, ... Camvia(TM) (maribavir) in liver transplant patients; ... of Camvia in stem cell transplant patients; ...
... TORONTO, Oct. 30 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer ... room, will host a conference call and live webcast,to discuss the ... ... 4:30 pm, Eastern Time, Dial ...
... Oct. 30 GeneGo, Inc., the leading,systems biology ... its flagship data analysis suite MetaCore(TM). The platform,will ... is designed for,functional analysis of biological and chemistry ... autoimmune programs. "We are very pleased that ...
Cached Medicine News:Health News:ULURU Inc. Announces Odd-Lot Buy Back Offer 2Health News:Food 'tricks' that combat sneaky, creepy Halloween treats 2Health News:New Drug Promising Against Tough-to-Treat Kidney Cancer 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:Novadaq announces third quarter 2007 conference call and webcast 2Health News:Novadaq announces third quarter 2007 conference call and webcast 3
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) ... of Pharma in 2014 - a Perspective of Mental ... their offering. For the first time, in ... reputation of the pharmaceutical industry held by patient groups ... of patient organisations representing all therapy areas. ...
(Date:4/16/2015)... 2015 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for the treatment of central ... for the first quarter of 2015 on Wednesday, May ... The Company will host a conference call at 4:30 ... Vanda management will discuss the first quarter 2015 financial ...
(Date:4/16/2015)... April 16, 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... 31, 2015 on Wednesday, May 6, 2015, following the close ... an investor conference call and live webcast on the same ... update and discuss the financial results.  To ... , under the "Investors" link.  Please log onto the webcast ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3
... on Valopicitabine Combined,with an Investigational Protease Inhibitor, ... Pharmaceuticals, Inc. today announced results from two ... valopicitabine (NM283) and,pegylated interferon alfa-2a (Pegasys(R)) in ... the genotype-1,strain of the hepatitis C virus ...
... /PRNewswire-FirstCall/ --,CuraGen Corporation announced today that new ... (HDAC) inhibitor being,investigated for the treatment of ... the prevention of severe oral mucositis,will be ... Cancer,Research (AACR) 2007 Annual Meeting in Los ...
Cached Medicine Technology:Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
... This test device is ... detection of IgG and IgM ... human serum. The test is ... for diagnosis of Dengue viral ...
... Gonorrhea is intended for the immunochromatographic, ... swab samples.,Smart Strip Gonorrhea is based ... for the determination of gonorrhea antigen ... from urinary system as an aid ...
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: